This randomized trial evaluates N-acyl sulfonamides to reduce biofilm in Staphylococcus aureus, suggesting a novel treatment approach.
Biofilm-associated Staphylococcus aureus infections remain difficult to treat using conventional antibiotics. Herein, we report the synthesis and biological evaluation of lauric acid- and BDSF-derived N- acyl sulfonamides as antibiofilm and antivirulence agents. Structure–activity relationship (SAR) analysis identified 4- tert -butylphenyl sulfonyldodecenamide ( 59 ) as a lead compound with a minimum inhibitory concentration of 5 μg/mL and >60% inhibition of MSSA and MRSA biofilm formation at sub-minimum inhibitory concentration levels. Microscopy confirmed marked reductions in biofilm biomass and thickness. The lead compound synergized with gentamicin and tobramycin, suppressed hemolysis, slime production, metabolic activity, and cell-surface hydrophobicity, and induced intracellular reactive oxygen species. qRT-PCR revealed downregulation of key virulence regulators ( agrA, RNAIII, saeR, and seb ), indicating disruption of quorum-sensing circuitry. SAR modeling rationalized steric and electronic requirements for activity. Low toxicity in plant, nematode, and mammalian models highlights bioisosteric N -acyl sulfonamides as promising antivirulence scaffolds for combating S. aureus biofilm infections.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: